Skip to content

The Effect of Aquacel® Ag+ Extra Dressing on Wound Biofilms

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02228122
Enrollment
10
Registered
2014-08-28
Start date
2014-10-31
Completion date
2015-05-31
Last updated
2015-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Foot Wounds, Diabetes

Keywords

Chronic wounds, Biofilms, Bacteria

Brief summary

The purpose of the research is to assess the effects of Aquacel Ag+ Extra dressing on chronic wound bacterial biofilms

Detailed description

Background: Chronic wounds and wound infections can be costly, resulting in prolonged hospital stays and an increased risk of secondary infection and septicaemia. In the UK the management of chronic venous leg ulcers is estimated to cost £1 billion/year, with surgical site infections requiring approximately 6.5 days additional hospital stay. Chronic wounds typically harbour a wide variety of bacteria; heavy bacterial colonisation and subsequent biofilm formation has been cited as a factor which induces a chronic inflammatory state and delays healing times. AQUACEL®Ag+ Extra is a soft conformable flat sheet nonwoven fabric dressing, which forms a gel when it becomes wet. Its physical characteristics have the potential to increase the speed of antimicrobial action of silver and its effectiveness against any recalcitrant wound bioburden. Removing these potential barriers to healing may help towards wound progression. Aim: This is a pilot study to investigate the effects of Aquacel Ag+ Extra dressing on chronic wound bacterial biofilms. Wound debridement tissue will be assessed for the presence/absence of in situ biofilms which will be monitored over 4 weeks and compared to the baseline (non-treatment) sample. Additionally, we will evaluate reductions in wound volume over the treatment period.

Interventions

DEVICEAquacel® Ag+ Extra

Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.

Sponsors

ConvaTec Inc.
CollaboratorINDUSTRY
Dr Angela Oates
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Provided written informed consent * Be over 18 years of age * Must have a chronic foot wound greater than 4 weeks in duration * Be willing and able to attend the clinic for the required study visits -

Exclusion criteria

* Subjects with a history of sensitivity to any one of the components of the device being studied * Subjects who have any other medical condition which, according to the investigator justifies exclusion from the study * Subjects who are currently participating in or have been on a clinical study within the last 4 weeks.

Design outcomes

Primary

MeasureTime frameDescription
A measure of the presence/absence of biofilms in over five weeks when exposed to Aquacel Ag+ Extra dressing.up to day 28Wound debridement tissue derived from standard of care will be retained for analysis up to Day 28. Tissue to be sectioned and analysed for the presence or absence of bacterial biofilms.

Secondary

MeasureTime frameDescription
Size of the wound and an indicator of healingup to day 28Weekly measurements of wound size

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026